Clinical Characteristics of Myositis Associated with Graft-Versus-Host Disease.
Curr Rheumatol Rep
; 23(5): 30, 2021 04 24.
Article
en En
| MEDLINE
| ID: mdl-33893887
ABSTRACT
PURPOSE OF REVIEW Recipients of allogeneic hematopoietic stem cell transplantation (HSCT) are at increased risk for inflammatory myositis; histological subsets reported include dermatomyositis, necrotising myopathy and chronic graft-versus-host disease (cGVHD)-related myositis. Though corticosteroids and various immunosuppressive therapies have been used, there is a lack of consensus guidelines dictating therapy. RECENT FINDINGS:
Recent evidence suggests the fascia as a preferential target in cGVHD myositis, with conditioning regimens promoting fascial microtrauma. Positron emission tomography (PET) can be a useful diagnostic tool, and case reports suggest that the Bruton's tyrosine kinase inhibitor ibrutinib may have therapeutic potential. Emerging therapies include targeted B cell depletion with rituximab, and extracorporeal photophoresis. Clinicians need to be vigilant for the development of inflammatory myositis post-allogeneic HSCT as most patients respond to treatment. Advances in immunohistochemistry to determine the dominant cell type and cytokine profile may enable targeted and individualised therapies.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Trasplante de Células Madre Hematopoyéticas
/
Enfermedad Injerto contra Huésped
/
Miositis
Tipo de estudio:
Etiology_studies
/
Guideline
/
Risk_factors_studies
Idioma:
En
Revista:
Curr Rheumatol Rep
Asunto de la revista:
REUMATOLOGIA
Año:
2021
Tipo del documento:
Article